Format

Send to

Choose Destination
Future Oncol. 2017 Jan;13(2):125-133. Epub 2016 Sep 12.

Targeting acute myeloid leukemia with TP53-independent vosaroxin.

Author information

1
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Vosaroxin is a quinolone compound that intercalates DNA and induces TP53-independent apoptosis, demonstrating activity against acute myeloid leukemia (AML) in Phase I-III trials. Here, we examine vosaroxin's mechanism of action and pharmacology, and we review its use in AML to date, focusing on details of individual clinical trials. Most recently, when combined with cytarabine in a randomized Phase III trial (VALOR), vosaroxin improved outcomes versus cytarabine alone for relapsed/refractory AML in patients older than 60 years and for patients in early relapse. We consider its continued role in the context of a multifaceted strategy against AML, including its current use in clinical trials. Prospective use will define its role in the evolving landscape of AML therapy.

KEYWORDS:

acute myeloid leukemia; antineoplastic agents; intercalating agents; prospective studies; vosaroxin

PMID:
27615555
PMCID:
PMC5144553
DOI:
10.2217/fon-2016-0300
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Financial & competing interests disclosure F Ravandi has received research funding and Honoraria from Sunesis and has been the member of advisory boards with Sunesis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center